Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria

Antje Banning, Christina Gülec, Juha Rouvinen, Steven J. Gray, Ritva Tikkanen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Aspartylglucosaminuria (AGU) is a lysosomal storage disorder that is caused by genetic deficiency of the enzyme aspartylglucosaminidase (AGA) which is involved in glycoprotein degradation. AGU is a progressive disorder that results in severe mental retardation in early adulthood. No curative therapy is currently available for AGU. We have here characterized the consequences of a novel AGU mutation that results in Thr122Lys exchange in AGA, and compared this mutant form to one carrying the worldwide most common AGU mutation, AGU-Fin. We show that T122K mutated AGA is expressed in normal amounts and localized in lysosomes, but exhibits low AGA activity due to impaired processing of the precursor molecule into subunits. Coexpression of T122K with wildtype AGA results in processing of the precursor into subunits, implicating that the mutation causes a local misfolding that prevents the precursor from becoming processed. Similar data were obtained for the AGU-Fin mutant polypeptide. We have here also identified small chemical compounds that function as chemical or pharmacological chaperones for the mutant AGA. Treatment of patient fibroblasts with these compounds results in increased AGA activity and processing, implicating that these substances may be suitable for chaperone mediated therapy for AGU.

Original languageEnglish (US)
Article number37583
JournalScientific Reports
Volume6
DOIs
StatePublished - Nov 23 2016

Fingerprint

Aspartylglucosaminuria
Aspartylglucosylaminase
Pharmacology
Therapeutics
Mutation
Lysosomes
Intellectual Disability
Glycoproteins
Fibroblasts

ASJC Scopus subject areas

  • General

Cite this

Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria. / Banning, Antje; Gülec, Christina; Rouvinen, Juha; Gray, Steven J.; Tikkanen, Ritva.

In: Scientific Reports, Vol. 6, 37583, 23.11.2016.

Research output: Contribution to journalArticle

Banning, Antje ; Gülec, Christina ; Rouvinen, Juha ; Gray, Steven J. ; Tikkanen, Ritva. / Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria. In: Scientific Reports. 2016 ; Vol. 6.
@article{837b155fe8d8463ba93d76daa7451a43,
title = "Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria",
abstract = "Aspartylglucosaminuria (AGU) is a lysosomal storage disorder that is caused by genetic deficiency of the enzyme aspartylglucosaminidase (AGA) which is involved in glycoprotein degradation. AGU is a progressive disorder that results in severe mental retardation in early adulthood. No curative therapy is currently available for AGU. We have here characterized the consequences of a novel AGU mutation that results in Thr122Lys exchange in AGA, and compared this mutant form to one carrying the worldwide most common AGU mutation, AGU-Fin. We show that T122K mutated AGA is expressed in normal amounts and localized in lysosomes, but exhibits low AGA activity due to impaired processing of the precursor molecule into subunits. Coexpression of T122K with wildtype AGA results in processing of the precursor into subunits, implicating that the mutation causes a local misfolding that prevents the precursor from becoming processed. Similar data were obtained for the AGU-Fin mutant polypeptide. We have here also identified small chemical compounds that function as chemical or pharmacological chaperones for the mutant AGA. Treatment of patient fibroblasts with these compounds results in increased AGA activity and processing, implicating that these substances may be suitable for chaperone mediated therapy for AGU.",
author = "Antje Banning and Christina G{\"u}lec and Juha Rouvinen and Gray, {Steven J.} and Ritva Tikkanen",
year = "2016",
month = "11",
day = "23",
doi = "10.1038/srep37583",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria

AU - Banning, Antje

AU - Gülec, Christina

AU - Rouvinen, Juha

AU - Gray, Steven J.

AU - Tikkanen, Ritva

PY - 2016/11/23

Y1 - 2016/11/23

N2 - Aspartylglucosaminuria (AGU) is a lysosomal storage disorder that is caused by genetic deficiency of the enzyme aspartylglucosaminidase (AGA) which is involved in glycoprotein degradation. AGU is a progressive disorder that results in severe mental retardation in early adulthood. No curative therapy is currently available for AGU. We have here characterized the consequences of a novel AGU mutation that results in Thr122Lys exchange in AGA, and compared this mutant form to one carrying the worldwide most common AGU mutation, AGU-Fin. We show that T122K mutated AGA is expressed in normal amounts and localized in lysosomes, but exhibits low AGA activity due to impaired processing of the precursor molecule into subunits. Coexpression of T122K with wildtype AGA results in processing of the precursor into subunits, implicating that the mutation causes a local misfolding that prevents the precursor from becoming processed. Similar data were obtained for the AGU-Fin mutant polypeptide. We have here also identified small chemical compounds that function as chemical or pharmacological chaperones for the mutant AGA. Treatment of patient fibroblasts with these compounds results in increased AGA activity and processing, implicating that these substances may be suitable for chaperone mediated therapy for AGU.

AB - Aspartylglucosaminuria (AGU) is a lysosomal storage disorder that is caused by genetic deficiency of the enzyme aspartylglucosaminidase (AGA) which is involved in glycoprotein degradation. AGU is a progressive disorder that results in severe mental retardation in early adulthood. No curative therapy is currently available for AGU. We have here characterized the consequences of a novel AGU mutation that results in Thr122Lys exchange in AGA, and compared this mutant form to one carrying the worldwide most common AGU mutation, AGU-Fin. We show that T122K mutated AGA is expressed in normal amounts and localized in lysosomes, but exhibits low AGA activity due to impaired processing of the precursor molecule into subunits. Coexpression of T122K with wildtype AGA results in processing of the precursor into subunits, implicating that the mutation causes a local misfolding that prevents the precursor from becoming processed. Similar data were obtained for the AGU-Fin mutant polypeptide. We have here also identified small chemical compounds that function as chemical or pharmacological chaperones for the mutant AGA. Treatment of patient fibroblasts with these compounds results in increased AGA activity and processing, implicating that these substances may be suitable for chaperone mediated therapy for AGU.

UR - http://www.scopus.com/inward/record.url?scp=84996548960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996548960&partnerID=8YFLogxK

U2 - 10.1038/srep37583

DO - 10.1038/srep37583

M3 - Article

C2 - 27876883

AN - SCOPUS:84996548960

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 37583

ER -